There are more and more data concerning the role of cellular metabolism in innate immune cells, such as macrophages or conventional dendritic cells. However, few data are available currently concerning plasmacytoid dendritic cells (PDC), another type of innate immune cells. These cells are the main type
Introduction
More and more data are available concerning the role of cellular metabolism in innate immune cells, such as macrophages or conventional dendritic cells (cDC) [1] [2] [3] . However, few data are available currently concerning plasmacytoid dendritic cells (PDC) . PDC belong to the family of dendritic cells (DC) and possess specific features that distinguish them from cDC. PDC represent the main type I interferon (IFN) secreting cells and play a critical role in antimicrobial immune responses. The involvement of PDC through IFN-α secretion has also been reported in several autoimmune diseases (see section 2.4). Furthermore, PDC release other pro-inflammatory cytokines, as well as immunoregulatory factors. In these ways, they may exert pro-inflammatory functions or, on the contrary, participate in tolerance mechanisms. In this Review article, based on recent publications [4] [5] [6] , we will discuss how the innate immune functions of PDC may be modulated by or dependent on the glycolytic pathway (also known as glycolysis) and lipid metabolism, including the metabolism of cholesterol and fatty acids. Before that, we will describe the innate functions of PDC. PDC also have the capacity to present antigens to T cells and to polarize CD4 + helper T cell responses, as well as those interacting with B cells 7 . These functions will not be discussed in this article, since no sufficient data are available concerning the impact of metabolism on the capacity of PDC to interact with the adaptive immune system. Although the "immunometabolism" (as defined in Ref# 2 ) includes six metabolic pathways (glycolysis, the tricarboxylic acid [TCA] cycle, the pentose phosphate pathway, fatty acid oxidation, fatty acid synthesis and amino acid metabolism) that influence immune cell effector functions 2 , this article will focus on glycolysis and lipid metabolism (extended to the cholesterol metabolism). Concerning amino acid metabolism, PDC innate functions have been shown to be modulated by mammalian target of rapamycin (mTOR) signaling. This central metabolic regulator, mTOR can sense amino acid sufficiency in lysosomes, and promotes mRNA translation and lipid synthesis to support cell growth and proliferation 2 . Furthermore, mTOR, through its association with regulatory-associated protein of mTOR (RAPTOR), constitutes the mTOR complex 1 (mTORC1), which is connected with other metabolic pathways (see section 3.1). This will be discussed briefly, since the role of mTOR in innate immune cell functions has been reviewed recently 3, 8 . Finally, concerning amino acid metabolism, PDC are able to sense amino acid deficiency through their expression of GCN2 (general control nonderepressible 2) serine/threonine kinase. Indeed, the suppression of interleukin (IL)-6 production in PDC by indoleamine 2,3-dioxygenase (IDO) involves GCN2 kinase 9 (see section 2.3).
What are the main roles of the immunometabolism in immune cells? First of all, this is a way to provide energy. Cells need energy to execute cellular functions, such as survival, proliferation or cytokine secretion. This energy is provided as adenosine triphosphate (ATP) by several pathways. The first is glycolysis, which involves the conversion of glucose to pyruvate in the cytosol. The second pathway is the TCA cycle (also called the Krebs cycle), which donates electrons to the electron transport chain located in the mitochondria to fuel oxidative phosphorylation or respiration (OXPHOS). This OXPHOS process generates ATP in the mitochondria. Other substrates, such as fatty acids via β-oxidation (also called fatty acid oxidation [FAO] ), can replenish the TCA cycle to fuel OXPHOS 10 . In addition to substrates used for energy production and de novo biosynthesis, mitochondrial metabolic pathways (such as the TCA, FAO, or OXPHOS) provide substrates for epigenetic modifications of DNA and histones 11, 12 . This is the case, for instance, of acetyl-CoA for histone acetylation, which is associated with active transcription 11 . This connects mitochondrial metabolism to epigenetic regulation 12 . This specific aspect will be briefly discussed in the Conclusions of this article.
The innate immune functions of plasmacytoid dendritic cells
PDC belong to the DC family and possess specific features that distinguish them from cDC 13 . These features include: the capacity to rapidly and massively produce type I IFN (i.e., IFN-α/β), the expression of a particular set of pathogen-recognition receptors (PRR), leading to the recognition of specific pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern (DAMP) molecules, as well as a preferential localization in lymphoid organs 7 .
PDC were firstly identified in human as the major IFN-α producing cells, and thus initially called IPC (IFN-α producing cells) 14, 15 . After this characterization in human, its murine PDC counterpart was then isolated [16] [17] [18] [19] 14, 23, 30 . The microenvironment in which PDC are present may influence oxygen and nutrient availability, which impacts on metabolic pathways (see section 3).
2.2. Type I IFN and pro-inflammatory cytokines secreted by PDC PDC constitute a DC subset, specialized in antimicrobial immune responses. This occurs mainly through a rapid type I IFN (IFN-α/β) production 7, 31, 32 . Selective depletion of PDC by genetic approaches supports the critical role of PDC for early IFN-α production after microbial infections [33] [34] [35] . The type I IFN response is triggered by Toll-like receptor (TLR) signaling after PAMP recognition.
Compared to cDC, PDC express a limited number of PRR. TLR 7/9 are expressed by both human and mouse PDC 7, 36 . These two endoplasmic TLRs allow PDC to recognize cytosine-phosphate guanosine (CpG)-rich unmethylated DNA from bacteria and DNA viruses, 7, 31, 37 , as well as viral single-stranded RNA (ssRNA), 31, 38, 39 , respectively. In addition, PDC are able to recognize via TLR7/9 mammalian nucleic acids 40 , in particular when these nucleic acids are complexed or associated with antimicrobial peptides (e.g., LL37) 41, 42 . Once PDC have sensed pathogens or DAMP through endoplasmic TLR, signaling is mediated via MyD88 (myeloid differentiation factor 88), a docking protein for IRAK1⁄4 (IL-1R-associated kinase 1/4), and the ubiquitin ligase TRAF6 (tumor necrosis factor [TNF] receptor-associated factor 6). IFN-regulatory factor 7 (IRF7) is then phosphorylated and translocates into the nucleus to induce type I IFN gene and IFNinducible gene transcription (Figure 1) 43 . This is true for human PDC
36
. Concerning mouse PDC, other intermediates may participate in type I IFN mRNA transcription in the TLR-dependent IRF7 signaling pathway. This involves a complex, associating TRAF3, IRAK1, osteopontin, PI3K (phosphatidylinositol 3-kinase) and IKKα (IκB kinase-α) 36 . A critical role of PI3K has also been reported for type I IFN production by human PDC
44
. In addition, in TLR7-or TLR9-activated human PDC, TRAF6 can also recruit TAK1 (transforming growth factor [TGF]-β-activating kinase; also known as MAP3K7 for mitogen-activated protein kinase kinase kinase 7) to trigger the synthesis of pro-inflammatory cytokines via NF-κB activation 36 . In mouse PDC, TAK-1/MAP3K7 activates the mitogen-activated protein kinase (MAPK) pathway that upregulates costimulatory molecule expression (e.g., CD40, CD80 or CD86) 36 . Both human and mouse PDC have been shown to secrete TNF-α [4] [5] [6] 45, 46 , 45, 46 , IL-8 [45] [46] [47] or granulocyte macrophage colony-stimulating factor (GM-CSF) 45 . This TLR-induced cytokine synthesis is regulated in PDC by the translocation of NF-κB, p38 MAPK and c-Jun N-terminal kinase (JNK) into the nucleus. In human PDC, the association of NF-κB p65 and p50 subunits with IRF5 appears to be the master inducer of IL-6 mRNA transcription 36 . Depending on the TLR9 ligand used, the cytokine response can be different. For instance, type A CpG-containing oligonucleotide (CpG-ODN) (CpGA) induces mainly type I IFN production, whereas type B CpG-ODN (CpGB) induces pro-inflammatory cytokine secretion and upregulation of co-stimulatory molecules 48 . ; this is out of the scope of this review).
When one evokes cellular metabolism, cell survival has to be discussed. IL-3 has been identified as a critical factor for the development and survival of PDC 64, 65 . This cytokine interacts with the IL-3 receptor associating two chains, the common chain CD131 and the IL-3Rα chain (CD123) that is highly expressed by PDC. Signaling through this receptor involves Janus kinase 2 (JAK2), Src kinases, transcription factors STAT3/STAT5 (signal transducer and activator of transcription 3/5) and Akt ( Figure 1) 66 . Another cytokine that shares the common chain CD131 and influences PDC survival with nearly the same signaling pathway is GM-CSF (Figure 1) 
65
. Finally, PDC express IFNAR, the membrane receptor for type I IFN (IFN-α or IFN-β) that consists of two subunits, IFNAR1 and IFNAR2. Engagement of this receptor by its ligand activates JAK1 (associated with IFNAR1) and tyrosine kinase 2 (associated with IFNAR2) that phosphorylate and activate STAT1 and STAT2, respectively ( Figure 1) 66,67 .
Implications of PDC in diseases
Before discussing the role of immunometabolism, the role of PDC in beneficial and detrimental immune responses will be briefly detailed. As type I IFN producing cells, PDC play a major beneficial role in antimicrobial immune responses 7 . However, uncontrolled IFN-α production in acute viral infection may be detrimental to the host. Moreover, high levels of type I IFN released by PDC may be detrimental in chronic inflammatory or autoimmune diseases 7, 54, [68] [69] [70] [71] . This is the case of systemic lupus erythematosus (SLE) 66, 75 . Atherosclerotic plaques are enriched in lipids. This may modify the lipid metabolism of infiltrated PDC by the uptake of lipidenriched lipoproteins or oxidized lipoproteins, and subsequently PDC functions (see section 3.3.3). Finally, insufficient or exhausted production of IFN-α during chronic viral infections (e.g., chronic hepatitis C virus or HIV) has also been reported 76, 77 . Thus, the metabolism of PDC may be pharmacologically modified in order to restore type I IFN production.
The influence of the metabolism on innate immune functions of plasmacytoid dendritic cells

PDC innate immune functions and mTOR signaling
The kinase mTOR is a key regulator of different biological processes, including metabolism 8 . This is a serine/threonine protein kinase that senses and integrates signals (such as nutrients and oxygen) originating from the extracellular milieu, as well as intracellular signals 78 . In fact, mTOR is the catalytic subunit of two different complexes, mTORC1 and mTORC2. As mentioned briefly in the Introduction, mTORC1 is connected with several metabolic pathways. Indeed, mTORC1 promotes glycolysis through hypoxia-inducible factor 1α (HIF-1α) 8 , as well as cholesterol and fatty acid synthesis using TCA cycle intermediates through a pathway involving sterol regulatory element-binding proteins (SREBP) and the nuclear receptor, peroxisome proliferatoractivated receptor (PPAR) γ
8
. Cholesterol and fatty acids are used as "building blocks" 8 for complete maturation of endoplasmic reticulum (ER) and Golgi apparatus. Both organelles can promote the transport of pro-inflammatory cytokines within the cell that precedes their secretion 8 . In addition, mTORC1 can have a negative effect on mitochondrial OXPHOS by inducing the expression of type I IFN and production of nitric oxide, which subsequently promotes aerobic glycolysis 8 . This has been well described in macrophages 8 .
Concerning PDC innate immune functions, mTOR plays an important role in type I IFN production 79 . The TLR9 ligand, CpGA, stimulates the rapid phosphorylation of mTOR and its downstream targets, the p70 ribosomal S6 kinase 1 and the eukaryotic translation initiation factor 4E-binding protein (4E-BP) 79 . Thus, mTOR is involved in the TLR9-induced type I IFN signaling pathway (Figure 2 ). Using the mTORC1 inhibitor rapamycin, the same authors demonstrated that TLR7/9-mediated production of type I IFN is inhibited in both human and mouse PDC 79 . These data have been confirmed in vivo using live attenuated viral yellow fever vaccine 79 . The virus responsible for yellow fever is an ssRNA virus and TLR7 recognizes ssRNA 38 . Rapamycin may act at two levels: i) by inactivating via the inhibition of 4E-BP phosphorylation the nuclear translocation of IRF7 required The endosomal TLR7 pathway in human blood-derived PDC promotes early glycolysis (within minutes following TLR7 triggering; green font and green arrows), as attested by increased ECAR (extracellular acidification rate; a reflection of lactate excretion). This implicates the HIF-1α molecule that increases the GLUT1 glucose transporter allowing extracellular glucose entry and stimulates some enzymes involved in glycolysis (HK or PFK). Glycolysis in human PDC is required for TLR7-induced type I IFN production. A potential link with the activation of the mTORC1 complex can be seen, since this complex is activated by both endosomal TLR7 and TLR9 pathway in mouse and human PDC. Inhibitors of mTORC1 (RAP), of TLR7 signaling (chlor.), and of glycolysis (2-DG) are written in blue font. (B) The TLR9 pathway in mouse bone marrow-derived PDC promotes late glycolysis (after 24 hours) (grey font and grey arrows) via a type I IFN/IFNAR loop. This pathway also promotes fatty acid synthesis, FAO coupled with OXPHOS to generate ATP in a PPARα-dependent mechanism (violet font and violet arrows). This TLR9 pathway implicates the activation of mTORC1 in both mouse and human PDC. Specific inhibitors of fatty acid synthesis (C75), pyruvate entry in the mitochondrion (UK5099), TCA cycle (TOFA) or FAO (etoxomir) are written in blue font and have been used to demonstrate the promotion of fatty acid synthesis, FAO and OXPHOS inTLR9-induced type I IFN production. For more details, please refer to the main text. Abbreviations (not defined in the main text): HK, hexokinase; PFK, phosphofructokinase; RAP., rapamycin; chlor., chloroquine.
for type I IFN gene transcription; and ii) by blocking the formation of the TLR9-MyD88 complex via the p70 ribosomal S6 kinase 1 78 . In addition to type I IFN production, the inhibition of mTORC1 reduces TLR7/9-induced TNF and IL-6 production by human and mouse PDC 79 . Overall, mTOR signaling is involved in the TLR9-induced type I IFN signaling pathway and blocking mTORC1 inhibits TLR7/9-stimulated secretion of pro-inflammatory cytokines (i.e., type I IFN, TNF and IL-6) by PDC. Thus, the use of mTOR inhibitors may block the detrimental pro-inflammatory functions of PDC in inflammatory disorders, but may also prevent the beneficial antimicrobial response of PDC.
Lastly, mTORC1 stimulates glycolysis in innate immune cells, at least via HIF-1α induction, but also through the increased expression of the glucose transporter 1 (GLUT1) at the cell surface (Figure 2) 8 . GLUT1 enhances glucose uptake from the extracellular milieu 8 . Thus, the implication of mTOR signaling pathway in the response of PDC to TLR9 ligand 79 suggests that glycolysis may be triggered in the cells. This will be discussed in the next section.
PDC innate immune functions and glycolysis
The glycolytic pathway (also known as glycolysis) involves the uptake of extracellular glucose (i.e., present in the microenvironment) and its conversion in the cytosol to generate pyruvate 2 . Most pyruvate is then excreted from the cells as lactate after a process called aerobic glycolysis. This is a relatively inefficient pathway for the generation of energy (i.e., cellular ATP) compared to the TCA cycle coupled to OXPHOS 80 . The preferential use of glycolysis versus the TCA cycle and OXPHOS depends on oxygen availability 2, 80 . Glycolysis is favored during hypoxia, a situation encountered, for instance, in joints during rheumatoid arthritis or in the inflamed colon during Crohn's disease 80 -PDC can be present in both inflamed tissues (i.e., the synovial fluid 81-83 and the colon 73, 84 ). This energy provided by glycolysis may represent the resources necessary for cytokine secretion, since PDC does not proliferate in the same way as adaptive cells (i.e., T cells). However, PDC become highly secretory upon activation 7 . Finally, growth factors triggering PI3K and MAPK in their signaling pathway promote, in theory, the cellular use of glycolysis 2 . This may be the case when PDC are stimulated by TLR7/9 ligands (see previous section).
The exposure of human PDC to two different ssRNA viruses, influenza virus (Flu) and Rhinovirus (RV) -triggering the TLR7 pathway via ssRNA recognition 38 -activates HIF-1α 4 , a major regulator of metabolism (Figure 2A) . Indeed, HIF-1α is critical for glycolysis to generate ATP, since it induces the expression of different glycolytic enzymes, such as hexokinase and phosphofructokinase 80 . In addition to HIF-1α activation, the TLR7 agonist gardiquimod, as well as Flu and RV, induces early glycolysis (within minutes) in human PDC, as attested by elevated extracellular acidification rate (ECAR; a reflection of lactate secretion in extracellular milieu, an indicator of glycolysis in real time) and elevated rates of lactate production 4 . Moreover, the inhibition of glycolysis by 2-deoxyglucose (2-DG; a glycolytic inhibitor) impairs ssRNA virus-or TLR7 ligand-induced type I IFN by PDC, as well as the upregulation of HLA-DR, CD80 and CD86 at PDC cell surface 4 . Furthermore, 2-DG inhibits the increase of IFNA, CD80 and CD86 mRNA induced by exposure to Flu 4 . This suggests that glycolysis induced by the TLR7 pathway regulates these genes at the transcriptional level. The involvement of the TLR7 pathway in glycolysis was supported by the use of chloroquine, known to disrupt endosomal acidification required for TLR7 signaling 85 . Chloroquine treatment inhibits the lactate production by PDC in response to Flu or gardiquimod 4 . Overall, ssRNA viruses enhance glycolysis in human PDC via the TLR7 pathway (Figure 2A ). This finding was confirmed in vivo, since viral infection using live attenuated influenza vaccine increases glycolysis in ex vivo isolated human PDC and correlates with IFN-α production by these cells 4 .
These data contrast with a recent report showing that mouse PDC activation in response to the TLR9 ligand, CpGA, is not accompanied by a rapid change in ECAR (i.e., during the first 150 minutes). This contrasts with data obtained in the same experiments using cDC -as a control of PDC -stimulated by either lipopolysaccharide, Poly(I:C) or CpGA 5 . However, glycolysis is detected late (24 hours) in TLR9-stimulated mouse PDC 5 . Moreover, the authors also studied the role of the TLR7 pathway in mouse PDC, but not extensively. Again, they found a delayed activation of glycolysis after stimulation of mouse PDC with the TLR7 agonist imiquimod . Nevertheless, all these data support that glycolysis plays a role as a source of energy in the production of type I IFN, pro-inflammatory cytokines (IL-6 and TNF) and costimulatory molecule upregulation by PDC in response to TLR7/9 activation. The modulation of this metabolic pathway may limit uncontrolled pro-inflammatory cytokines by PDC in pathological situations or may restore type I IFN production in chronic infectious diseases.
PDC innate immune functions and lipid metabolism
In this section, we will discuss fatty acid metabolism, including fatty acid oxidation (FAO; also known as mitochondrial β-oxidation) and fatty acid synthesis, as well as cholesterol metabolism. Lipid metabolism is regulated by many key enzymes. Some of these enzymes involved in de novo lipid synthesis are controlled by lipid-activated nuclear receptors, such as liver X receptor (LXR) or PPAR. The genes coding for these enzymes are thus called LXR or PPAR target genes, respectively. Among these LXR or PPAR target genes, one may cite FASN coding for fatty acid synthase [86] [87] [88] . These LXR or PPAR target genes code not only for enzymes involved in lipid metabolism, but also for transcription factors and transporters, and regulate also to glucose or amino acid metabolism. This is the case of the transcription factors, SREBP, or of glucose or cholesterol transporters involved in nutrient entry (e.g., the GLUT1 glucose transporter) or efflux, such as ATP binding cassette (ABC) transporters A1 and G1 (ABCA1 and ABCG1, respectively) involved in cholesterol efflux 2, 86, 87, 89, 90 . PPAR and LXR are both mainly found associated with retinoid X receptor (RXR) to form a heterodimer. Considered as permissive heterodimer receptors, they can be activated by the ligands of each partner (e.g., PPAR or RXR ligands; LXR or RXR ligands) 88, 90 . While the involvement of these nuclear receptors in innate immune responses is well described for macrophages and cDC 90 , few data are available for PDC. Here, we will discuss how lipid metabolism modulates PDC innate immune functions and how PDC activation by TLR ligands or other stimuli modifies lipid metabolism.
Fatty acid oxidation.
The FAO pathway allows the conversion of fatty acids into numerous products in the mitochondria. These products, such as acetyl-CoA, NADH (nicotinamide adenine dinucleotide dehydrogenase) and FADH 2 (the fully reduced form of flavin adenine dinucleotide [FAD] ), can be used in the TCA cycle and the electron transport chain to generate energy 2 . As discussed before, normoxia supports the TCA cycle and OXPHOS, while hypoxia via HIF-1α activation followed by the induction of glycolytic enzymes leads to glycolysis 2,80 . The TCA cycle coupled to OXPHOS is the major metabolic pathway used by most quiescent or non-proliferating cells 2 .
A recent well-received manuscript reports that FAO and mitochondrial OXPHOS play a critical role in murine PDC activation by the TLR9 pathway ( Figure 2B ) 5 . This is particularly well demonstrated for type I IFN production by these cells 5 . Mouse PDC stimulated by the TLR9 ligand, CpGA, exhibit an increase of basal oxygen consumption rate (OCR) and spare respiratory capacity (SRC) 5 . Both increased basal OCR and SRC are indicators of FAO. To directly demonstrate that CpGA increases FAO, the authors used etomoxir, an irreversible inhibitor of carnitine palmitoyl transferase I 2 . This enzyme is responsible for the entry of activated fatty acids (i.e., medium-chain and long-chain fatty acids conjugated with carnitine) into mitochondria for FAO 2 . Etomoxir inhibits both the increase of basal OCR and SRC induced by TLR9 ligand stimulation. Moreover, etomoxir limits the production of IFN-α and pro-inflammatory cytokines (TNF-α and IL-6) by PDC in response to CpGA stimulation. This inhibition of TLR9 activation by etomoxir also prevents the upregulation of CD86 expression at PDC cell surface 5 . Overall, TLR9-induced mouse PDC activation is accompanied by an increased FAO, and stimulation of this metabolic pathway is required for proinflammatory cytokine secretion and PDC maturation (i.e., CD86 upregulation).
An increase of basal OCR and SRC attesting for FAO has also been observed after the activation of mouse PDC by the TLR7 agonist imiquimod. Treatment of mouse PDC by etomoxir inhibits imiquimod-induced IFN-α production 5 , suggesting that FAO is also required for type I IFN production in response to TLR7 ligand. Implication of FAO in vivo was assessed using etomoxir and mice infected with the ssRNA lymphocytic choriomeningitis virus (LCMV). Etomoxir-treated and LCMV-infected mice exhibit reduced circulating IFN-α 3 days after infection and significantly more LCMV are detected in the liver and spleen of etomoxir-treated versus untreated infected mice 5 . This demonstrates the in vivo relevance of these data.
Changes in basal OCR are not detected at early time points after murine PDC activation by CpGA, but this requires new gene transcription. This may suggest that IFN-α production and IFNAR signaling induced by CpGA stimulation may be responsible for these changes in PDC metabolism. Indeed, treatment with IFN-α alone is sufficient to induce increased FAO in mouse PDC 5 . Thus, increased FAO induced by CpGA stimulation in mouse PDC are therefore the results of an autocrine or paracrine loop involving the type I IFN signaling pathway.
One goal of the FAO pathway is to generate energy, by the production of a high number of ATP molecules 2 . This occurs in fact by fueling OXPHOS 2 . To definitively demonstrate the implication of energy provided by FAO coupled to OXPHOS in type I IFNinduced mouse PDC activation, ATP was quantified in response to IFN-α and different inhibitors were used 5 . Metabolic reprogramming of mouse PDC induced by IFN-α leads to enhanced ATP availability 5 . The quantity of ATP in response to CpGA activation is significantly reduced by the inhibition of either FAO (using etomoxir), pyruvate import into mitochondria required for the TCA cycle (using UK5099) or fatty acid synthesis (using tall oil fatty acid [TOFA] ) 5 . This confirms that type I IFN stimulation of mouse PDC generates significant amounts of ATP via the FAO pathway. This pathway fuels OXPHOS in this setting and is itself fueled by fatty acid synthesis, as demonstrated by the use of the inhibitor TOFA ( Figure 2B ).
The pathways responsible for the changes in metabolism induced by type I IFN in mouse PDC were studied by an unbiased RNAseq based approach 5 . This analysis shows that OXPHOS is the major network induced by type I IFN, and FAO is connected to this network. Furthermore and surprisingly, this analysis reveals also a PPARα gene signature 5 . While PPARγ is expressed in macrophages and cDC 90 , the PPARα isoform is mainly and highly expressed in metabolic active tissues, such as the liver or brown adipose tissues 88 . After having confirmed that the PPARα isoform is expressed by bone marrow-derived and splenic mouse PDC, a PPARα antagonist, GW6471 was used 5 . GW6471 blocks both IFN-α production and the increase of basal OCR in response to CpGA activation. Furthermore, increased basal OCR and SRC in mouse PDC are observed after incubation with a PPARα agonist gemfibrozil, as well as with the combined PPARα and PPARγ agonist, muraglitazar 5 . Overall, this indicates that PPARα is involved in FAO and OXPHOS induced by CpGA activation ( Figure 2B ). This PPARα pathway in PDC functions will be discussed later in this review together with the other lipidactivated nuclear receptor, LXR (see the following two sections).
Fatty acid synthesis.
The fatty acid synthesis pathway allows cells to generate lipids that are necessary for cellular growth and proliferation 2 . Fatty acid synthesis is performed in the cytosol, and it uses citrate from the TCA cycle and exported from the mitochondria into the cytosol to generate fatty acids ( Figure 2B 93 . ABCG1 is rather localized within the cell and seems to move sterols between intracellular compartments 88 . Figure 3 . Cholesterol metabolism controls plasmacytoid dendritic cell (PDC) innate functions. Activation of the LXR pathway by "physiological" oxidized cholesterol derivatives (oxysterols) or synthetic LXR agonists induces the decrease of PDC intracellular cholesterol content by stimulating cholesterol efflux through ABCA1 cholesterol transporter, inhibiting cholesterol entry by decreasing LDL or VLDL receptor (LDLR and VLDLR, respectively) expression and inhibiting de novo cholesterol biosynthesis (also known as the mevalonate pathway). Cholesterol efflux via ABCA1 requires cholesterol acceptors, such as APOA1, and immature HDL (HDL2/3) to generate mature HDL that transport cholesterol towards the liver. Activation of this LXR pathway inhibits TLR7-induced NF-κB activation and phosphorylation of STAT5 and Akt in response to IL-3 stimulation (green font and green arrows). Inhibition of cholesterol biosynthesis by statins (violet font and arrows) inhibits TLR7/9-induced IRF7 translocation in the nucleus, as well as phosphorylation of p38 kinase, and consequently the production of type I IFN. For more details and abbreviations, please refer to the main text.
ABCA1 is more dedicated to extrude cholesterol derivatives outside the cell 88 . Cholesterol regulates critical cellular functions, including plasma membrane formation and fluidity, allowing the clustering of receptors into lipid rafts for efficient signaling 92 . These latter functions are implicated in signaling pathway regulation. Localization of signaling complexes within the lipid rafts is critical for certain receptors.
Cholesterol homeostasis is regulated at least by LXR. These nuclear receptors are expressed as two isoforms, including the ubiquitous LXRβ isoform and LXRα, which exhibits an expression restricted to cells with high cholesterol turnover (e.g., macrophages) 86, 90, 94 . The LXR pathway is activated by intermediates from the cholesterol biosynthesis (e.g., desmosterol), endogenous oxidized cholesterol derivatives (called oxysterols, such as 22(R)-hydroxycholesterol [22RHC]), and synthetic agonists (e.g., T0901317 or GW3965) 86 . LXR activation upregulates the expression of several genes involved in cholesterol homeostasis (i.e., LXR target genes), including: ABCA1, ABCG1
87
, and APOE (related to cholesterol efflux) 88, 95 , as well as the 'inducible degrader of the low-density lipoprotein receptor' (IDOL), preventing cholesterol uptake through LDLR/VLDLR degradation 96 . Overall, these mechanisms triggered by LXR activation participate in the decrease of intracellular cholesterol content. Again, the LXR pathway has been studied extensively in the regulation of macrophage functions, including cholesterol homeostasis and inflammatory responses, as well as apoptotic cell uptake (a process called efferocytosis) 90 . However, the role of cholesterol and LXR begins only to be deciphered in PDC innate functions.
Inhibition of the mevalonate pathway (i.e., de novo cholesterol biosynthesis) by statins (simvastatin and pitavastatin) blocks TLR7-and TLR9-induced type I IFN production by human PDC (Figure 3 ) 97 . This has been demonstrated with blood-derived PDC obtained from healthy donors, as well as from patients with SLE 97 . Statin treatment also inhibits TNF secretion by human PDC in response to either TLR7 (loxoribine) or TLR9 (CpGA) ligands 97 . These data have been confirmed in vivo using ssRNA Sendai virus 97 . Inhibition of de novo cholesterol synthesis by statins in PDC interferes with the p38 MAPK pathway, Akt and nuclear translocation of IRF7 (Figure 3) 
97
. Finally, the inhibitory effect of statins has been tested in vivo and on mouse PDC, since treatment of C57BL/6 mouse with statins before triggering type I IFN production by ssRNA poly(U) injection decreases circulating IFN-α 97 . Thus, the inhibition of cholesterol synthesis in PDC is associated with an anti-inflammatory response. This confirms the global anti-inflammatory effects of statins 98 .
Recently, we reported that the LXRβ isoform is expressed in human PDC 6 , as well as in mouse PDC (unpublished study, Ceroi A, Bonnefoy F, Angelot-Delettre F and Saas P), and that this LXR pathway is fully functional 6 . Using freshly bloodisolated human PDC and a PDC cell line CAL-1, a functional LXR pathway has been demonstrated, as attested by increased LXR target gene expression in response to three different LXR agonists (two synthetic agonists and an oxysterol, 22RHC that represents a more physiological LXR ligand). The activation of the LXR pathway in PDC reduces the pro-inflammatory cytokine secretion (IL-6 and TNF-α) induced by TLR7 triggering 6 . Moreover, these data obtained in human PDC from healthy donors 6 and in leukemic PDC 99 demonstrate that the LXR pathway interferes with TLR7-induced NF-κB activation at different levels, including a transcriptional repression of p65 NF-κB subunit and a reduced phosphorylation of this NF-κB subunit (Figure 3 ) 6, 99 . Pretreatment of leukemic PDC with synthetic LXR agonists also reduces Akt and STAT5 phosphorylation in response to IL-3 (Figure 3) 
99
. LXR stimulation in the PDC cell line CAL-1 increases cholesterol efflux via the upregulation of cholesterol transporters, such as ABCA1 (Figure 3) 
. Although the cholesterol efflux was only tested using this CAL-1 PDC cell line 99 , upregulation of cholesterol transporters at mRNA and protein levels was also observed in human blood-derived PDC treated with LXR agonists 6 . Stimulation of cholesterol efflux by the addition of a cholesterol acceptor, APOA1, amplifies the effects of LXR activation in leukemic PDC, including inhibition of the IL-3 signaling pathway (Akt and STAT5 phosphorylation) and cell survival (Figure 3) 
. This confirms the previous data using statins 97 , and suggests that modifying cholesterol homeostasis in PDC can be useful to limit their detrimental role in pathological situations. Alteration of PDC survival after modification of intracellular cholesterol content using either statins 97 or LXR agonists 99 is only detected at highest concentrations (100 µM). In addition, LXR activation in human PDC also increases microparticle internalization via the phosphatidylserine receptor (PtdSerR), . This contrasts with data obtained in macrophages in which LXR stimulation induces another PtdSerR, called Mer-TK (Mer tyrosine kinase) 100 . Nevertheless, this suggests that stimulation of PDC via the LXR pathway may improve their capacity to eliminate circulating pro-inflammatory microparticles. Triggering LXR pathway using LXR agonists before exposure to pro-inflammatory endothelial-derived microparticles prevents NF-κB activation and pro-inflammatory cytokine production by human PDC 6 . This sustains an anti-inflammatory role of LXR agonists.
A discrepancy exists concerning type I IFN production after inhibition of cholesterol biosynthesis (using statins 97 ) and the massive decrease of intracellular cholesterol content (using LXR agonists 6, 99 ). Inhibition of type I IFN has been reported after statin treatment 97 , but not after cholesterol deprivation 6 . This may be due to a compensatory mechanism, since massively decreasing the pool size of synthesized cholesterol alone induces spontaneous type I IFN production associated with an antiviral immunity in bone marrow-derived macrophages 101 . This response occurs via the cGAS/STING/TBK1/IRF3 pathway 101 . Thus, LXR agonists could inhibit TLR7/9-mediated type I IFN by interfering with this signaling pathway together with massively decreasing the intracellular cholesterol pool size. This could explain why IFN-α production is unaffected after LXR agonist treatment of PDC. Another difference between the effect of statins and LXR agonists lies in the inhibition of IRF7 (but not of NF-κB phosphorylation by statins) 97 , whereas the activation of the LXR pathway in PDC blocks NF-κB activation via several mechanisms 6,99 (see above). Overall, the manipulation of cholesterol metabolism in PDC can be proposed to limit their pro-inflammatory functions.
Conclusions
Here, we summarize data currently available showing that several metabolic pathways are triggered in PDC by different stimuli, including pro-inflammatory signals (e.g., TLR7/9 ligands or endothelial-derived microparticles), as well as anti-inflammatory signals (e.g., platelet-derived microparticles). These pathways comprise: the mTOR signaling pathway, glycolysis, FAO coupled to OXPHOS, fatty acid synthesis and cholesterol metabolism. All of these pathways are connected together, and they are globally necessary for efficient type I IFN production by PDC in response to TLR7/9-mediated activation. Few data are available, but it seems that induction of pro-inflammatory cytokines (e.g., TNF, IL-6 and IL-8) and costimulatory molecules (i.e., CD80 or CD86) also need most of these metabolic pathways. On the contrary, alteration of cholesterol metabolism associated with decreased intracellular cholesterol content either after inhibition of de novo cholesterol synthesis or LXR activation inhibits the pro-inflammatory functions of PDC. These data suggest that pharmacological manipulation of the host metabolism may be useful to reprogram altered PDC immune functions.
Since cellular metabolism is highly dependent on the microenvironment (oxygen availability and nutrients), changes in the local tissue microenvironment may modulate PDC innate immune functions. This modulation of metabolism may result from exogenous metabolites that diffuse passively or through transporters into the PDC. Among these metabolites, one may find ligands of lipid-activated nuclear receptors, such as LXR or PPAR 3, 90 . Microenvironment and metabolic pathways may be modulated or controlled by microbiota. A recent study analyzed germ-free mice mono-colonized with each of the 53 human-resident bacterial species and the consequences of each bacterium on different immune cell subsets 102 . Among these 53 bacteria, some bacteria were identified as modifying PDC frequencies in the colon and the small intestine 102 . Among the genes for which their expression was correlated with PDC frequencies, the authors identified IFNinducible signature transcripts, but also transcripts involved in lipid and protein metabolic pathways. Moreover, the Hif1a transcript coding for the metabolism regulator HIF-1α was also associated with PDC frequencies 102 . This suggests a connection between PDC frequencies in the gastro-intestinal tract and metabolic pathways and nutrients/metabolites provided by microbiota.
We discussed above the connection of metabolism with epigenetic regulation. While few data are available concerning epigenetic regulation of PDC innate immune functions, it has been shown that the inhibitor of histone deacetylase, valproic acid, alters human PDC functions, including the production of pro-inflammatory cytokines (IFN-α TNF and IL-6) in response to TLR9 ligand, CpGA 103 . Thus, it remains to be determined how metabolism may regulate epigenetic modification of DNA and histones in PDC.
Lastly, acute perturbations in intracellular lipid content, via for instance LXR activation, may also influence cell proliferation and survival by inducing significant ER stress 88 . This cellular organelle is responsible for protein folding. The result of this ER stress is an accumulation of unfolded proteins. This pathway leads also to the expression of the transcription factor X-box binding protein 1 (XBP1), which induces lipid synthesis. XBP1 has been shown to regulate cDC infiltrating ovarian tumors; accumulation of lipids in the tumor-infiltrating cDC following ER stress and XBP1 activation reduces their ability to present antigens, and thus impairs anti-tumor T-cell responses 104 . Whether this may occur in infiltrating PDC remains to be analyzed. Nevertheless, PDC have been shown to express XBP1 105 . This factor can be targeted with bortezomib, which maintains ER homeostasis 105 . This can be an additional way related to metabolism to block pro-inflammatory PDC functions. In conclusion, a better understanding of PDC immunometabolism may help to limit the detrimental effect of these cells and increase their beneficial role in the future.
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The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. This review provides a balanced and comprehensive overview of the latest discoveries about the role of metabolism in plasmacytoid dendritic cell innate functions. This is a very original topic based on recent data supporting the idea that the glycolytic pathway as well as lipid metabolism may modulate the production of type I IFN by pDC or may be involved in this function after TLR7/9 triggering. In addition, this review provides new clues on how these metabolic pathways may be harnessed in pathophysiological contexts where pDC play a detrimental role.
This review has a comprehensive view of all relevant literature in the field and summarized very well the fundamental concepts, but there are some minor concerns that need to be addressed as below.
Abstract is clearly written, but the text could be reduced by omitting the section about the differences related to the origin of pDC. We only have a few comments on the manuscript:
The discussion of PDC implication in disease could be expanded. In particular, authors could discuss the role of PDC in the tumor microenvironment. It is known that metabolism plays an important role in tumor development and antitumor immunity. Can this also be through affecting PDCs? Is there a crosstalk between PDC biology, metabolism, and tumor progression? Several articles in the past few years have addressed the function of PDC in cancer and could serve as a basis for a discussion. Other diseases could also be discussed in more details, in particular autoimmunity. Indeed, the pathways involved in PDC activation in disease context may be slightly different from exogenous purified TLR ligands, due to the diversity of stimuli and the complexity of the inflammatory microenvironments.
Figure 2 is a bit too dense and confusing. We suggest to clarify it removing or reorganizing some of the information.
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